UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 296

Sortiert nach

Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma

PloS one, 2013-12, Vol.8 (12), p.e83244-e83244

2013

Volltextzugriff (PDF)

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial

Blood, 2013-01, Vol.121 (3), p.468-475

2013

Volltextzugriff (PDF)

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo

Blood, 2010-11, Vol.116 (22), p.4578-4587

2010

Volltextzugriff (PDF)

Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks

Nature communications, 2016-06, Vol.7 (1), p.11938-11938, Article 11938

2016

Volltextzugriff (PDF)

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

Blood, 2011-09, Vol.118 (9), p.2530-2540

2011

Volltextzugriff (PDF)

The Genomics of Hairy Cell Leukaemia and Splenic Diffuse Red Pulp Lymphoma

Cancers, 2022-01, Vol.14 (3), p.697

2022

Volltextzugriff (PDF)

Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial

Journal of clinical oncology, 2011-06, Vol.29 (16), p.2223-2229

2011

Volltextzugriff (PDF)

A unique genome in EBV-positive BL

Blood, 2019-03, Vol.133 (12), p.1269-1270

2019

Volltextzugriff (PDF)

Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation

The Journal of experimental medicine, 2011-07, Vol.208 (7), p.1389-1401

2011

Volltextzugriff (PDF)

Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

Clinical cancer research, 2015-09, Vol.21 (18), p.4174-4183

2015

Volltextzugriff (PDF)

Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma

Scientific reports, 2019-07, Vol.9 (1), p.10444-9, Article 10444

2019

Volltextzugriff (PDF)

ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial

Haematologica (Roma), 2014-04, Vol.99 (4), p.736

2014

Volltextzugriff (PDF)

Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation

Molecular & cellular proteomics, 2018-04, Vol.17 (4), p.776-791

2018

Volltextzugriff (PDF)

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

Nature genetics, 2009-04, Vol.41 (4), p.446-449

2009

Volltextzugriff (PDF)

Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial

Journal of clinical oncology, 2012-12, Vol.30 (36), p.4524-4532

2012

Volltextzugriff (PDF)

Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival

Journal of clinical oncology, 2005-05, Vol.23 (13), p.2971-2979

2005

Volltextzugriff (PDF)

DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1

Experimental cell research, 2009-10, Vol.315 (17), p.2941-2952

2009

Volltextzugriff (PDF)

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation

Haematologica (Roma), 2010-10, Vol.95 (10), p.1705-1712

2010

Volltextzugriff (PDF)

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

The Lancet (British edition), 2004-01, Vol.363 (9403), p.105-111

2004

Volltextzugriff (PDF)

Mutation Status of the Residual ATM Allele Is an Important Determinant of the Cellular Response to Chemotherapy and Survival in Patients With Chronic Lymphocytic Leukemia Containing an 11q Deletion

Journal of clinical oncology, 2007-12, Vol.25 (34), p.5448-5457

2007

Volltextzugriff (PDF)

Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis

Clinical cancer research, 2007-09, Vol.13 (17), p.5048-5055

2007

Volltextzugriff (PDF)

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

Blood, 2003-06, Vol.101 (12), p.4944-4951

2003

Volltextzugriff (PDF)

1 – 25 von 296

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(286)
Mit Volltextzugriff
(274)

Publikationsform

Sprache

Englisch
(296)
Japanisch
(33)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(155)
Science & Technology
(153)
Life Sciences & Biomedicine
(145)
Hematology
(96)
Female
(83)
Male
(78)
Biological And Medical Sciences
(69)
Medical Sciences
(67)
Aged
(66)
Leukemia, Lymphocytic, Chronic, B-Cell - Genetics
(65)
Middle Aged
(61)
Mutation
(59)
Hematologic And Hematopoietic Diseases
(54)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(50)
Prognosis
(50)
Oncology
(46)
Adult
(44)
Medicin Och Hälsovetenskap
(43)
Aged, 80 And Over
(35)
Chronic Lymphocytic Leukemia
(28)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(137)
British Journal Of Haematology
(24)
Haematologica
(15)
Journal Of Clinical Oncology
(10)
Genes Chromosomes & Cancer
(7)
Leukemia
(7)
Leukemia Research
(6)
Leukemia & Lymphoma
(5)
Clinical Cancer Research
(4)
Clinical Lymphoma, Myeloma And Leukemia
(4)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo

Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial

Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

The Genomics of Hairy Cell Leukaemia and Splenic Diffuse Red Pulp Lymphoma

Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial

A unique genome in EBV-positive BL

Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation

Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma

ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial

Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial

Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival

Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial

DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

Mutation Status of the Residual ATM Allele Is an Important Determinant of the Cellular Response to Chemotherapy and Survival in Patients With Chronic Lymphocytic Leukemia Containing an 11q Deletion

Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients

Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

Suchergebnisse filtern